meaxin 100 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - imatinib - 44 - cytostatica
meaxin 400 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - imatinib - 44 - cytostatica
meaxin 400 mg dispergovateľné tablety
krka, d.d., novo mesto, slovinsko - imatinib - 44 - cytostatica
meaxin 100 mg dispergovateľné tablety
krka, d.d., novo mesto, slovinsko - imatinib - 44 - cytostatica
imatinib vipharm 400 mg
vipharm s.a., poľsko - imatinib - 44 - cytostatica
imatinib vipharm 100 mg
vipharm s.a., poľsko - imatinib - 44 - cytostatica
imatinib stada 100 mg filmom obalené tablety
stada arzneimittel ag, nemecko - imatinib - 44 - cytostatica
imatinib mylan 400 mg
mylan ireland limited, Írsko - imatinib - 44 - cytostatica
imatinib mylan 100 mg
mylan ireland limited, Írsko - imatinib - 44 - cytostatica
lorviqua
pfizer europe ma eeig - lorlatinib - karcinóm, pľúc bez malých buniek - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.